Table 3.

Associations between AcPGP and COPD exacerbations

	No severe AECOPD (n = 155)	Severe AECOPD (n = 18)	P-value
Sputum AcPGP			0.019
Q1  Q2  Q3  Q4	42 (28%) 41 (27%) 38 (25%) 31 (20%)	2 (11%) 1 (6%) 7 (39%) 8 (44%)
Sputum AcPGP above median	69 (45%)	15 (83%)	0.002
Plasma AcPGP			0.96
Q1  Q2  Q3  Q4	37 (24%) 38 (25%) 41 (27%) 39 (25%)	5 (28%) 4 (22%) 4 (22%) 5 (28%)
Plasma AcPGP above median	73 (47%)	11 (61%)	0.27

Data expressed as n (percent). Chi square testing was used for analyses